Ongoing
1. SERB (PI)-CRF:
Hippocampal E2, neuronal dysfunctions and sexual dimorphism in adult rats:
Effects of chronic arsenic exposure; Sanctioned Rs 47,08,240, March-2021-2024.
2. SERB-SUPRA (Co-PI): Anti-gerogenic
Therapy to Augment Lifespan and Health span by Bioactive Peptides from Rasayana
Herbs:Generation of PaC for the First-in-class Ayurveda-based Peptides; Sanctioned
Rs 15,93,000, August 2020-2023.
3. DBT (PI): 70 Lakhs; Study on the Intergenerational Effect of Maternal
Vitamin D3 Deficiency on Cognition and Hippocampal Neurons in Rats; Sanctioned Rs
68,35,024, August 2021-2024.
4. ICMR (PI): Hippocampal
E2, cognition loss and sexual dimorphism in adult rats: A comparative study on
chronic Bisphenol S, F and A exposures; Sanctioned Rs
60,00,000, January 2022-2025.
Completed
5. SERB (PI): To study the role of Gpr40 and PPARγ
signaling induced by Docosahexaenoic Acid in alleviating heavy-metal(s)
mediated astrocyte damage in the developing brain-
Rs 30,67,000, June 2017-2020.
6. SERB
(PI): Mechanism of white matter damage by a mixture of As, Cd and Pb:
Investigating the role of glutamate metabolism during CNS development; Rs
48,48,000, May 2014- 2017
7. DBT (PI): 60 lakhs; Mechanism underlying white
matter damage by metals during brain development: Role of glia-neuron interaction-Rs 64,00,000, June 2014-November
2017
8. DST (PI): 20 Lakhs; Characterisation of pathogenic
mechanism of action of metal mixture on neurodevelopment-2009-2012
9. ICMR (PI): 40 Lakhs; Characterisation of the
protective role of omega3 fatty acid against neurodevelopmental damage in metal
mixture exposed rat model-2009-1012
10. Empower (PI; CSIR-competitive grant): 50
lakhs Unraveling New Pathobiological Mechanism of Developmental Brain Damage by
Environmental Toxicants-2010-2013.
Patent Granted: “Model
of Alzheimer’s disease”,
European patent granted; No.
0036NF2013-EP
Technologies available for transfer
A “Model of Alzheimer’s disease (AD)” features a non-transgenic rat model for early AD, using a metal mixture of As, Cd and Pb, characterized by enhanced synergistic amyloidogenicity in rat cortex and hippocampus. This model can serve as a tool for (a) AD-directed drug screening, and (b) determining mechanism of AD pathogenicity. It features induction of the Abeta-mediated apoptosis and induction of inflammation in rodent brain. The invention features novel astrocyte and neuronal cellular models for AD, using a metal mixture of As, Cd and Pb, characterized by enhanced synergistic amyloidogenicity. This model can serve as a tool for (a) AD-directed drug screening in astrocytes and neurons, and (b) determining mechanism of AD pathogenicity in cells. It features induction of the Abeta-mediated apoptosis and induction of inflammation in astrocytes and neurons.